Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology

Keita Kajino,Akihisa Tokuda,Tsuyoshi Saitoh

DOI: https://doi.org/10.1093/jb/mvae021

2024-02-21

The Journal of Biochemistry

Abstract:Abstract Morphinan-based opioids, derived from natural alkaloids like morphine, codeine and thebaine, have long been pivotal in managing severe pain. However, their clinical utility is marred by significant side effects and high addiction potential. This review traces the evolution of the morphinan scaffold in light of advancements in biochemistry and molecular biology, which have expanded our understanding of opioid receptor pharmacology. We explore the development of semi-synthetic and synthetic morphinans, their receptor selectivity and the emergence of biased agonism as a strategy to dissociate analgesic properties from undesirable effects. By examining the molecular intricacies of opioid receptors and their signaling pathways, we highlight how receptor-type selectivity and signaling bias have informed the design of novel analgesics. This synthesis of historical and contemporary perspectives provides an overview of the morphinan landscape, underscoring the ongoing efforts to mitigate the problems facing opioids through smarter drug design. We also highlight that most morphinan derivatives show a preference for the G protein pathway, although detailed experimental comparisons are still necessary. This fact underscores the utility of the morphinan skeleton in future opioid drug discovery.

biochemistry & molecular biology

What problem does this paper attempt to address?

The paper attempts to address the issues of side effects and addiction associated with morphinan-based opioids in clinical applications. To tackle these challenges, the study reviews how advancements in biochemistry and molecular biology have driven the design and improvement of morphinan-based opioid scaffolds, and explores the development of selective receptor agonists and biased agonists.

Specifically, the paper focuses on the following points:
1. **Receptor Selectivity**: Developing selective agonists for κ (KOR) and δ (DOR) opioid receptors to separate therapeutic effects from adverse reactions.
2. **Biased Agonists**: Exploring agonists that preferentially activate the G protein signaling pathway rather than the β-arrestin pathway to reduce side effects.

Through these approaches, researchers aim to design new analgesics that can alleviate pain while avoiding the negative impacts associated with current opioid medications.